Trial reportBone marrow transplantation2006
High-dose melphalan (200 mg/m2) supported by autologous stem cell transplantation is safe and effective in elderly (>or=65 years) myeloma patients: comparison with younger patients treated on the same protocol.
Trial report in Bone marrow transplantation, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 98 citations in OpenAlex.
- Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study.Haematologica · 2016Trial
- Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.Bone marrow transplantation · 2015Trial
- Conditioning with melphalan 200 mg/mEuropean journal of haematology · 2022Article
- Gastrointestinal toxicity of high-dose melphalan in autologous hematopoietic stem cell transplantation: identification of risk factors and a benchmark for experimental therapies.Annals of hematology · 2021Article
- Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study.International journal of hematology · 2020Article
- Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study.Bone marrow transplantation · 2019Observational
- Challenges and Strategies in the Management of Multiple Myeloma in the Elderly Population.Current hematologic malignancy reports · 2019Review
- Stem-cell transplantation in multiple myeloma: how far have we come?Therapeutic advances in hematology · 2019Review
- Treatment of Multiple Myeloma in Elderly Patients: A Review of Literature and Practice Guidelines.Cureus · 2018Review
- Hematopoietic Cell Transplant (HCT) in the Elderly: Myths, Controversies and Unknowns.Drugs & aging · 2018Review
- Transplantation related toxicity and mortality in older autologous hematopoietic cell transplantation recipients.American journal of hematology · 2017Article
- Variability of high-dose melphalan exposure on oral mucositis in patients undergoing prophylactic low-level laser therapy.Lasers in medical science · 2017Article
- Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.Critical reviews in immunology · 2016Review
- High-dose therapy and autologous stem cell transplant in older adults with multiple myeloma.Bone marrow transplantation · 2015Article
- The impact of low-grade toxicity in older people with cancer undergoing chemotherapy.British journal of cancer · 2014Article
- Controversies in multiple myeloma: to transplant or not?Current hematologic malignancy reports · 2014Review
- Multiple myeloma in the older adult: better prospects, more challenges.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
- Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic.Journal of the National Comprehensive Cancer Network : JNCCN · 2014Article
- Autologous stem cell transplantation in elderly patients with multiple myeloma: past, present, and future.BioMed research international · 2014Review
- Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilities.Oncology reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Limited information is available on the feasibility and efficacy of autologous stem cell transplantation (ASCT) in multiple myeloma (MM) patients >65 years of age. In 1995-2005, 22 myeloma patients >or=65 years (median 68, eight >or=70) and 79 patients <65 years (median 57) were included in an identical treatment protocol. The first progenitor cell mobilization with cyclophosphamide plus granulocyte-colony stimulating factor (G-CSF) was successful in 95 and 96% of the patients, respectively. To date, 92 patients have received MEL (melphalan) 200 mg/m2 supported by ASCT. No early treatment-related deaths were observed among 22 elderly patients, whereas one younger patient died early. Engraftment and the need for supportive care were comparable between groups. The elderly patients tended to have more WHO grade 3-4 oral or gastrointestinal toxicity when compared to the younger patients (45 vs 23%, P=0.06). After ASCT, a complete response was observed in 44% of the elderly patients and 36% of the younger patients, respectively. No difference was observed between these age groups in progression-free survival (23 vs 21 months) or overall survival (57 vs 66 months) after ASCT. We conclude that MEL200 is a safe and efficacious treatment in selected elderly myeloma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.